Multivariate models using NULISAseq and plasma p‐tau217 for staging Alzheimer's disease
Of the separate assays for p-tau217, the Lumipulse assay demonstrated significantly better performance than the ALZpath assay to separate disease stages. Multivariate blood-based biomarker (BBM) models are significantly better at predicting the presence of A/T from A-T- as compared with any p-tau217 assay. Multivariate BBM models have higher area under the curve values to predict disease stage than Alamar and ALZpath p-tau217, but not Lumipulse p-tau217 during later disease stage comparisons.
Authors
- Vincent Doré (ORCID: https://orcid.org/0000-0002-8051-0558)
- James D. Doecke (ORCID: https://orcid.org/0000-0003-2863-0293)
- Christopher C. Rowe (ORCID: https://orcid.org/0000-0003-3910-2453)
- Jürgen Fripp
- Anthony W. Bannon
- Malleswari Challagundla
- Nils Boehm
- Azadeh Feizpour
- Colin L. Masters (ORCID: https://orcid.org/0000-0003-3072-7940)
- Edwin Stage
- Christopher Fowler (ORCID: https://orcid.org/0000-0003-1397-0359)
- Claudius Kleinert
- Larry D. Ward
Institutions
- The University of Melbourne (AU)
- Ludwigshafen University of Business and Society (DE)
- Florey Institute of Neuroscience and Mental Health (AU)
- AbbVie (United States) (US)
- Australian e-Health Research Centre (AU)
- Austin Health (AU)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/alz.70793
- Citations
- 3
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- Alzheimer's Association
- Biogen
- Alnylam Pharmaceuticals
- Commonwealth Scientific and Industrial Research Organisation
- Eisai
- Medical Research Council
- National Health and Medical Research Council